Evaluation of the beta-adrenoblocker atenolol efficacy in patients with arterial hypertension depending on renin-aldosterone blood profile


Cite item

Full Text

Abstract

Efficacy of beta-adrenoblocker atenolol use in mono- and combination therapy in patients with arterial hypertension (AH), distributed on the blood renin-aldosterone profile is evaluated. The study enrolled 656 patients with essential hypertension. Plasma renin activity (PRA; normal - 1.0-3.0 ng/ml/h) and aldosterone plasma concentration (APC; normal - 0.18-0.83 nmol/L or 5-23 ng/dL) were identified by radioimmunoassay technique. The PRA/APC ratio amount 5-23 is allowable. It is concluded that atenolol in monotherapy or in combination with nifedipine retard, enalapril and losartan has a pronounced hypotensive effect, leads to a normalization of all parameters of the renin-angiotensin-aldosterone system, regardless of the initial activity sympathoadrenal system in patients with PRA > 3.0 ng/ml/h. In the event of PRA ≤ 3.0 ng/ml/h, atenolol administration is effectually in combination with enalapril or losartan in the case of the initial high activity of sympathoadrenal system.

References

  1. Task Force Members, Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on b-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004;25:1341-62.
  2. Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the swidish trial in old patients with hypertension (STOP-Hypertension). Lancet 19991;338:1281-85.
  3. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients. Mortality results from the MAPHY study. Am J Hypertens 1991;4:151-58.
  4. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354:1751-56.
  5. Hanson L, Lindholm LH, Niskanen L, et al. for the Captopril Prevention Project (CAPP) study group. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on carciovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999;353:611-16.
  6. UK Prospective Diabetes Study (UKPDS) Group 1998. Tight blood pressure control and risk of macrovascular and microvascular complications in type 11 diabetes: UKPDS 38. Br Med J 1998;317:703-12.
  7. Dahlof B, Devereux RB, Kjeldsen SE, et al. For LIFE study group. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003.
  8. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
  9. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta blockers for hypertension. Cochrane Database Review 2007; 1: CD002003.
  10. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiolody. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-87.
  11. Sever PS, Dahlof B, Poulter NR, et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet 2005;366:895-906.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies